Strativa Pharmaceuticals has entered into an agreement with Swedish Orphan Biovitrum (Sobi) for the development and commercialization of Nascobal cyanocobalamin (Vitamin B12) nasal spray in Europe. Sobi plans to begin development for European approval in early 2011 and will help to finance an upgrade of Strativa’s facilities necessary to meet EU regulations. QOL Medical, which had a pre-existing agreement with Sobi, sold worldwide rights for the product to Strativa in 2009. According to Strativa, Nascobal will be its first product marketed outside of the United States. Read the company’s press release.
